1. Home
  2. ITRG vs TIL Comparison

ITRG vs TIL Comparison

Compare ITRG & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Integra Resources Corp.

ITRG

Integra Resources Corp.

HOLD

Current Price

$3.90

Market Cap

482.5M

ML Signal

HOLD

Logo Instil Bio Inc.

TIL

Instil Bio Inc.

HOLD

Current Price

$7.12

Market Cap

74.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ITRG
TIL
Founded
1997
2018
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
482.5M
74.7M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
ITRG
TIL
Price
$3.90
$7.12
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$4.13
$100.67
AVG Volume (30 Days)
1.9M
182.7K
Earning Date
11-12-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.08
N/A
Revenue
$219,125,000.00
N/A
Revenue This Year
$965.93
N/A
Revenue Next Year
$9.39
N/A
P/E Ratio
$51.50
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.79
$5.67
52 Week High
$4.69
$42.79

Technical Indicators

Market Signals
Indicator
ITRG
TIL
Relative Strength Index (RSI) 48.54 30.33
Support Level $3.69 $5.67
Resistance Level $4.10 $12.91
Average True Range (ATR) 0.23 0.74
MACD -0.08 -0.23
Stochastic Oscillator 17.50 20.44

Price Performance

Historical Comparison
ITRG
TIL

About ITRG Integra Resources Corp.

Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.

About TIL Instil Bio Inc.

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

Share on Social Networks: